Antidepressants in pregnancy: A systematic review

Australian and New Zealand Journal of Psychiatry

Volumn 44, Issue 11, 2010, Pages 978-996

  Udechuku, Adaobi ^a   Nguyen, Tram ^b   Hill, Rebecca ^c   Szego, Klara ^a  

^a ST JOHN OF GOD HOSPITAL   (Australia)

^b ROYAL WOMEN'S HOSPITAL   (Australia)

^c Mercy Mental Health   (Australia)

Author keywords

antidepressant agents; congenital malformations; developmental outcomes; neonatal outcomes; pregnancy outcomes

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; FLUOXETINE; FLUVOXAMINE; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; NEFAZODONE; PAROXETINE; REBOXETINE; SERTRALINE; TRAZODONE; VENLAFAXINE;

ADAPTATION; ALERTNESS; APGAR SCORE; BIRTH WEIGHT; CLINICAL PRACTICE; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONSTIPATION; DATA BASE; DISEASE ASSOCIATION; DRUG SAFETY; EYE MALFORMATION; HEART RIGHT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HUMAN; IRRITABILITY; LIMB REDUCTION DEFECT; MATERNAL HYPERTENSION; PERSISTENT PULMONARY HYPERTENSION; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; PRENATAL DRUG EXPOSURE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SCROTUM DISORDER; SIDE EFFECT; SOMNOLENCE; SPONTANEOUS ABORTION; STILLBIRTH; SYSTEMATIC REVIEW; UMBILICAL HERNIA;

ABNORMALITIES, DRUG-INDUCED; ABORTION, SPONTANEOUS; ANTIDEPRESSIVE AGENTS; BIRTH WEIGHT; DEPRESSIVE DISORDER; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREMATURE BIRTH; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS;

EID: 78049497951     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.3109/00048674.2010.507543     Document Type: Review

References (89)

1. Johnson GL. Birth outcomes in pregnant women taking fl uoxetine. J Fam Pract 1997; 44:32.
2. Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295:499-507. (Pubitemid 43200344)
3. Shadigian E, Bauer ST. Pregnancy-associated death: a qualitative systematic review of homicide and suicide. Obstet Gynecol Surv 2005; 60:183-90.
4. Oates M. Suicide: the leading cause of maternal death. B r J Psychiatry 2003; 183:279-81.
5. Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49:726-35. (Pubitemid 40100521)
6. Alder J, Fink N, Bitzer J, Hosli I, Holgreve W. Depression and anxiety during pregnancy: A risk factor for obstetric, fetal and neonatal outcome? A review of the literature. J Maternal Fetal Neonatal Medicine 2007; 20:189-209
7. Kurki T, Hiilesmaa V, Raitasalo R, Mattila H, Ylikorkala O. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000; 95:487-90.
8. Austin MP, Leader L. Maternal stress and obstetric and infant outcomes: epidemiological fi ndings and neuroendocrine mechanisms. Aust N Z J Obstet Gynaecol 2000; 40:331-7.
9. Murray L, Cooper P. Postpartum depression and child development. Psychol Med 1997; 27:253-60.
10. Oberlander TF, Misri S, Fitzgerald CE, Kostaras X, Rurak D, Riggs W. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004; 65:230-7.
11. Hendrick V, Stowe ZN, Altshuler LL, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003; 160:993-6.
12. Heikkinen T, Ekblad U, Kero P, Ekblad S, Laine K. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72:184-91.
13. Heikkinen T, Ekblad U, Palo P, Laine K. Pharmacokinetics of fl uoxetine and norfl uoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73:330-7.
14. Loughhead AM, Fisher AD, Newport DJ, Ritchie JC, Owens MJ, DeVane CL, et al. Antidepressants in amniotic fl uid: another route of fetal exposure. Am J Psychiatry 2006; 163:145-7.
15. Loughhead AM, Stowe ZN, Newport DJ, Ritchie JC, DeVane CL, Owens MJ. Placental passage of tricyclic antidepressants. Biol Psychiatry 2006; 59:287-90.
16. O'Brien L, Einarson TR, Sarkar M, Einarson A, Koren G. Does paroxetine cause cardiac malformations? J Obstet Gynaecol Can 2008; 30:696-701.
17. Rahimi R, Nikfar S, Abdollahi M. Pregnancy outcomes following exposure to serotonin reuptake inhibitors: a meta-analysis of clinical trials . Reprod Toxicol 2006; 22:571-5.
18. Einarson TR, Einarson A. Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies . Pharmacoepidemiol Drug Saf 2005; 14:823-7.
19. Bar-Oz B, Einarson T, Einarson A, Boskovic R, O'Brien L, Malm H, et al. Paroxetine and congenital malformations: meta-Analysis and consideration of potential confounding factors . Clin Ther 2007; 29:918-26.
20. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fl uoxetine . N Engl J Med 1996; 335:1010-5.
21. Diav-Citrin O SS, Weinbaum D, Wajnberg R, Avgil M, Gianantonio E, Clementi C, Weber-Schoendorfer C, Schaefer C and Ornoy A. Paroxetine and Fluoxetine in pregnancy: a prospective, multicentre, controlled observational study . British journal of Clinical Pharmacology 2008; 66:695-705.
22. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, et al. Pregnancy outcome following fi rst-trimester exposure to fl uoxetine (Prozac) . JAMA 1993; 269:2246-8. (Pubitemid 23120281)
23. Nulman I, Koren G. The safety of fl uoxetine during pregnancy and lactation . Teratology 1996; 53:304-8.
24. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study . JAMA 1998; 279:609-10.
25. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study . Am J Psychiatry 2001; 158:1728-30.
26. Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, et al. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy . Can J Psychiatry 2003; 48:106-10.
27. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study . Am J Obstet Gynecol 2005; 192:932-6. (Pubitemid 40311292)
28. Sivojelezova A, Shuhaiber S, Sarkissian L, Einarson A, Koren G. Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome . Am J Obstet Gynecol 2005; 193:2004-9. (Pubitemid 41737626)
29. Djulus J, Koren G, Einarson TR, Wilton L, Shakir S, Diav-Citrin O, et al. Exposure to mirtazapine during pregnancy: a prospective, comparative study of birth outcomes . J Clin Psychiatry 2006; 67:1280-4.
30. Einarson A, Pistelli A, DeSantis M, Malm H, Paulus WD, Panchaud A, et al. Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy . Am J Psychiatry 2008; 165:749-52.
31. Goldstein DJ, Corbin LA, Sundell KL. Effects of fi rst-trimester fl uoxetine exposure on the newborn . Obstet Gynecol 1997; 89(5 Pt 1):713-8.
32. Casper RC, Fleisher BE, Lee-Ancajas JC, Gilles A, Gaylor E, DeBattista A, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy . J Pediatr 2003; 142:402-8.
33. Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication . Am J Obstet Gynecol 2003; 188:812-5.
34. Wisner KL, Sit DK, Hanusa BH, Moses-Kolko EL, Bogen DL, Hunker DF, et al . Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes . Am J Psychiatry 2009; 166:557-66.
35. Kallen BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect . Reprod Toxicol 2003; 17:255-61.
36. Kallen BA, Otterblad Olausson P. Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations . Birth Defects Res A Clin Mol Teratol 2007; 79:301-8.
37. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy . Eur J Clin Pharmacol 1999; 55:503-8. (Pubitemid 29446550)
38. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy . Obstet Gynecol 2005; 106:1289-96.
39. Lennestal R, Kallen B. Delivery outcome in relation to maternal use of some recently introduced antidepressants . J Clin Psychopharmacol 2007; 27:607-13.
40. Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations . Epidemiology 2006; 17:701-4.
41. Cole JA, Ephross SA, Cosmatos IS, Walker AM. Paroxetine in the fi rst trimester and the prevalence of congenital malformations . Pharmacoepidemiol Drug Saf 2007; 16:1075-85.
42. Davis RL, Rubanowice D, McPhillips H, Raebel MA, Andrade SE, Smith D, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy . Pharmacoepidemiol Drug Saf 2007; 16:1086-94.
43. Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure . Am J Psychiatry 2002; 159:2055-61.
44. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes . Am J Obstet Gynecol 2006; 194:961-6.
45. Wichman CL, Moore KM, Lang TR, St Sauver JL, Heise RH, Jr., Watson WJ. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy . Mayo Clin Proc 2009; 84:23-7.
46. Rosa F. Medicaid antidepressant pregnancy exposure outcomes. Reproductive Toxicology [Abstract]. 1994; 8:444-5.
47. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage . Birth Defects Res B Dev Reprod Toxicol 2007; 80:18-27.
48. Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects . N Engl J Med 2007; 356:2684-92.
49. Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects . N Engl J Med 2007; 356:2675-83.
50. Ramos E, St-Andre M, Rey E, Oraichi D, Berard A. Duration of antidepressant use during pregnancy and risk of major congenital malformations . Br J Psychiatry 2008; 192:344-50.
51. Hemels ME, Einarson A, Koren G, Lanctot KL, Einarson TR. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis . Ann Pharmacother 2005; 39:803-9.
52. Lattimore KA, Donn SM, Kaciroti N, Kemper AR, Neal CR, Jr., Vazquez DM. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a metaanalysis . J Perinatol 2005; 25:595-604.
53. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy . Arch Pediatr Adolesc Med 2004; 158:312-6.
54. Costei AM, Kozer E, Ho T, Ito S, Koren G. Perinatal outcome following third trimester exposure to paroxetine . Arch Pediatr Adolesc Med 2002; 156:1129-32.
55. Zeskind PS, Stephens LE. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior . Pediatrics 2004; 113:368-75.
56. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data . Arch Gen Psychiatry 2006; 63:898-906.
57. Suri R, Altshuler L, Hellemann G, Burt VK, Aquino A, Mintz J. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth . Am J Psychiatry 2007; 164:1206-13.
58. Maschi S, Clavenna A, Campi R, Schiavetti B, Bernat M, Bonati M. Neonatal outcome following pregnancy exposure to antidepressants: a prospective controlled cohort study . BJOG 2008; 115:283-9.
59. Pearson KH, Nonacs RM, Viguera AC, Heller VL, Petrillo LF, Brandes M, et al. Birth outcomes following prenatal exposure to antidepressants . J Clin Psychiatry 2007; 68:1284-9.
60. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs . N Engl J Med 1997; 336:258-62.
61. Cohen LS, Heller VL, Bailey JW, Grush L, Ablon JS, Bouffard SM. Birth outcomes following prenatal exposure to fl uoxetine . Biol Psychiatry 2000; 48:996-1000.
62. Nulman I, Rovet J, Stewart DE, Wolpin J, Pace-Asciak P, Shuhaiber S, et al. Child development following exposure to tricyclic antidepressants or fl uoxetine throughout fetal life: a prospective, controlled study . Am J Psychiatry 2002; 159:1889-95.
63. Laine K, Kytola J, Bertilsson L. Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy . Ther Drug Monit 2004; 26:685-7.
64. Suri R, Altshuler L, Hendrick V, Rasgon N, Lee E, Mintz J. The impact of depression and fl uoxetine treatment on obstetrical outcome . Arch Womens Ment Health 2004; 7:193-200.
65. Oberlander TF, Warburton W, Misri S, Aghajanian J, Hertzman C. Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study . Br J Psychiatry 2008; 192:338-43.
66. Laine K, Heikkinen T, Ekblad U, Kero P. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations . Arch Gen Psychiatry 2003; 60:720-6.
67. Toh S, Mitchell AA, Louik C, Werler MM, Chambers CD, Hernandez- Diaz S. Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction . J Clin Psychopharmacol 2009; 29:555-60.
68. Ferreira E, Carceller AM, Agogue C, Martin BZ, St-Andre M, Francoeur D, et al. Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates . Pediatrics 2007; 119:52-9.
69. Eggermont E, Raveschot J, Deneve V, Casteels-van Daele M. The adverse infl uence of imipramine on the adaptation of the newborn infant to extrauterine life . Acta Paediatr Belg 1972; 26:197-204.
70. Cowe L, Lloyd DJ, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine . Br Med J (Clin Res Ed) 1982; 284:1837-8.
71. Ostergaard GZ, Pedersen SE. Neonatal effects of maternal clomipramine treatment . Pediatrics 1982; 69:233-4
72. Eggermont E. Withdrawal symptoms in neonates associated with maternal imipramine therapy . Lancet 1973; 2:680.
73. Idanpaan-Heikkila J, Saxen L. Possible teratogenicity of imipramine- chloropyramine . Lancet 1973 Aug 11; 2:282-4.
74. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report . Int J Psychiatry Med 1991; 21:157-71.
75. Levinson-Castiel R, Merlob P, Linder N, Sirota L, Klinger G. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants . Arch Pediatr Adolesc Med 2006; 160:173-6.
76. Boucher N, Bairam A, Beaulac-Baillargeon L. A new look at the neonate's clinical presentation after in utero exposure to antidepressants in late pregnancy . J Clin Psychopharmacol 2008; 28:334-9.
77. Schwarzer V, Heep A, Gembruch U, Rohde A. Treatment resistant hyperemesis gravidarum in a patient with type 1 diabetes mellitus: neonatal withdrawal symptoms after successful antiemetic therapy with mirtazapine . Arch Gynecol Obstet 2008; 277:67-9.
78. Sokolover N, Merlob P, Klinger G. Neonatal recurrent prolonged hypothermia associated with maternal mirtazapine treatment during pregnancy . Can J Clin Pharmacol 2008; 15:e188-90.
79. Eyal R, Yaeger D. Poor neonatal adaptation after in utero exposure to duloxetine . Am J Psychiatry 2008; 165:651.
80. Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al . Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn . N Engl J Med 2006; 354:579-87. (Pubitemid 43209105)
81. Kallen B, Olausson PO. Maternal use of selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn . Pharmacoepidemiol Drug Saf 2008; 17:801-6.
82. Andrade SE, McPhillips H, Loren D, Raebel MA, Lane K, Livingston J, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn . Pharmacoepidemiol Drug Saf 2009; 18:246-52.
83. Mattson SN, Eastvold AD, Jones KL, Harris JA, Chambers CD. Neurobehavioural follow-up of children prenatally exposed to fl uoxetine . Teratology [Abstract]. 1999; 59:376.
84. Misri S, Reebye P, Kendrick K, Carter D, Ryan D, Grunau RE, et al . Internalizing behaviors in 4-year-old children exposed in utero to psychotropic medications . Am J Psychiatry 2006; 163:1026-32.
85. Oberlander TF, Reebye P, Misri S, Papsdorf M, Kim J, Grunau RE. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy . Arch Pediatr Adolesc Med 2007; 161:22-9.
86. Norquay C. (Ed). Therapeutic Guidelines: Psychotropics Version 6 . West Melbourne, Victoria: Therapeutic Guidelines Limited; 2008.
87. National Institute of Health and Clinical Excellence: Antenatal and Postnatal Mental Health: Clinical Management and Service Guidance Clinical Guideline CG45. 2007 [cited 18 March 2010] Available from URL:
88. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al . The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists . Obstet Gynecol 2009; 114:703-13.
89. Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health . Acta Psychiatr Scand 2009.